natgillin/translations-raw huggingface dataset:
Because the number of patients with ITP is low, the disease is considered ‘rare’, and Nplate was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 27 May 2005.
Keďže je počet pacientov s ochorením ITP nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Nplate 27. mája 2005 označený za liek na ojedinelé ochorenia.
Because the number of patients with Leber's hereditary optic neuropathy is low, the disease is considered ‘rare’, and Raxone was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 15 February 2007.
Keďže počet pacientov s Leberovou hereditárnou optickou neuropatiou je nízky, táto choroba sa považuje za zriedkavú, a liek Raxone bol 15. februára 2007 označený za liek na ojedinelé choroby.
Because the number of patients with LEMS is low, the disease is considered ‘rare’, and Firdapse was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 18 December 2002.
Keďže je počet pacientov s ochorením LEMS nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Firdapse 18. decembra 2002 označený za liek na ojedinelé ochorenia.
Because the number of patients with Lennox-Gastaut syndrome is low, the disease is rare, and Inovelon was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 20 October 2004.
Keďže je počet pacientov s Lennox-Gastautovým syndrómom nízky, toto ochorenie sa považuje za zriedkavé, a preto bol liek Inovelon 20. októbra 2004 označený za liek na ojedinelé ochorenia.
Because the number of patients with limbal stem-cell deficiency due to burns to the eyes is low, the disease is considered ‘rare’, and Holoclar was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 7 November 2008.
Keďže je počet pacientov s deficienciou limbálnych kmeňových buniek v dôsledku popálenín v očiach nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Holoclar dňa 7. novembra 2008 označený za liek na ojedinelé ochorenia.
Because the number of patients with lysosomal acid lipase deficiency is low, the disease is considered ‘rare’, and Kanuma was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 17 December 2010.
Keďže je počet pacientov s deficitom lyzozómovej kyslej lipázy nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Kanuma dňa 17. decembra 2010 označený za liek na ojedinelé ochorenia.
Because the number of patients with malignant glioma is low, the disease is considered ‘rare’, and Gliolan was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 13 November 2002.
Keďže počet pacientov s malígnym gliómom je nízky, toto ochorenie sa považuje za zriedkavé a Gliolan bol 13. novembra 2002 označený za liek na ojedinelé ochorenia (liek, ktorý sa používa pri zriedkavých ochoreniach).
Because the number of patients with medullary thyroid cancer is low, the disease is considered ‘rare’, and Cometriq was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 6 February 2009.
Keďže je počet pacientov s medulárnym karcinómom štítnej žľazy nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Cometriq dňa 6. februára 2009 označený za liek na ojedinelé ochorenia.
Because the number of patients with MPS IVA is low, the disease is considered ‘rare’, and Vimizim was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 24 July 2009.
Keďže je počet pacientov s MPS IVA nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Vimizim dňa 24. júla 2009 označený za liek na ojedinelé ochorenia.
Because the number of patients with MPS VI is low, the disease is considered ‘rare’, and Naglazyme was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 14 February 2001.
Keďže je počet pacientov s ochorením MPS VI nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Naglazyme 14. februára 2001 označený za liek na ojedinelé ochorenia.
Because the number of patients with multiple myeloma is low, the disease is considered ‘rare’, and Darzalex was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 17 July 2013.
Keďže je počet pacientov s mnohopočetným myelómom nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Darzalex 17. júla 2013 označený za liek na ojedinelé ochorenia.
Because the number of patients with multiple myeloma is low, the disease is considered ‘rare’, and Farydak was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 8 November 2012.
Keďže je počet pacientov s mnohopočetným myelómom nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Farydak 8. novembra 2012 označený za liek na ojedinelé ochorenia.
Because the number of patients with multiple myeloma is low, the disease is considered ‘rare’, and Imnovid was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 8 October 2009.
Keďže počet pacientov s mnohopočetným myelómom je nízky, táto choroba sa považuje za zriedkavú, a preto bol liek Imnovid 8. októbra 2009 označený za liek na ojedinelé ochorenia.
Because the number of patients with multiple myeloma is low, the disease is considered ‘rare’, and Kyprolis was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 3 June 2008.
Keďže je počet pacientov s mnohopočetným myelómom nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Kyprolis 3. júna 2008 označený za liek na ojedinelé ochorenia.
Because the number of patients with multiple myeloma is low, the disease is considered ‘rare’, and Thalidomide Celgene was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 20 November 2001.
Keďže počet pacientov s mnohopočetným myelómom je nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Thalidomide Celgene 20. novembra 2001 označený za liek na ojedinelé ochorenia.
Because the number of patients with narcolepsy is low, the disease is considered ‘rare’, and Wakix was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 10 July 2007.
Keďže je počet pacientov s narkolepsiou nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Wakix 10. júla 2007 označený za liek na ojedinelé ochorenia.
Because the number of patients with neuroblastoma is low, the disease is considered ‘rare’, and Unituxin was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 21 June 2011.
Keďže je počet pacientov s neuroblastómom nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Unituxin dňa 21. júna 2011 označený za liek na ojedinelé ochorenia.
Because the number of patients with non-24-hour sleep-wake disorder is low, the disease is considered ‘rare’, and Hetlioz was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 23 February 2011.
Keďže je počet pacientov s poruchou 24-hodinového rytmu spánku a bdenia nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Hetlioz dňa 23. februára 2011 označený za liek na ojedinelé ochorenia.
Because the number of patients with osteosarcoma is low, the disease is considered ‘rare’, and Mepact was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 21 June 2004.
Keďže počet pacientov s osteosarkómom je nízky, choroba sa považuje za zriedkavú, a preto bol liek Mepact 21. júna 2004 označený za liek na ojedinelé ochorenia (liek, ktorý sa používa pri zriedkavých chorobách).
Because the number of patients with ovarian cancer is low, the disease is considered ‘rare’ and Lynparza was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 6 December 2007.
Keďže je počet pacientok s ovariálnym karcinómom nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Lynparza dňa 6. decembra 2007 označený za liek na ojedinelé ochorenia.
Because the number of patients with PAH is low, the disease is considered ‘rare’, and Opsumit was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 27 September 2011.
Keďže je počet pacientov s ochorením PAH nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Opsumit dňa 27. septembra 2011 označený za liek na ojedinelé ochorenia.
Because the number of patients with PAH is low, the disease is considered ‘rare’, and Volibris was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 11 April 2005.
Keďže je počet pacientov s PAH nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Volibris 11. apríla 2005 označený za liek na ojedinelé ochorenia.
Because the number of patients with pancreatic cancer is low, the disease is considered ‘rare’, and Onivyde was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 9 December 2011.
Keďže je počet pacientov s rakovinou pankreasu nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Onivyde 9. decembra 2011 označený za liek na ojedinelé ochorenia.
Because the number of patients with Pompe disease is low, the disease is considered ‘rare’, and Myozyme was designated as an ‘orphan medicine’ (a medicine used in rare diseases) on 14 February 2001.
Keďže je počet pacientov s Pompeho chorobou nízky, choroba sa považuje za zriedkavú, a preto bol liek Myozyme 14. februára 2001 označený za liek na zriedkavé choroby.
Because the number of patients with primary apnoea of premature newborns is low, the disease is considered ‘rare’, and Peyona was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 17 February 2003.
Keďže počet pacientov s primárnym apnoe v prípade narodených novorodencov je nízky, toto ochorenie sa považuje za zriedkavé, a preto bol liek Peyona 17. februára 2003 označený za liek na ojedinelé ochorenia.
Because the number of patients with primary IGF-1 deficiency is low, the disease is considered ‘rare’, and Increlex was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 22 May 2006.
Keďže počet pacientov s primárnou deficienciou IGF-1 je nízky, toto ochorenie sa považuje za zriedkavé, a preto bol liek Increlex 22. mája 2006 označený za liek na ojedinelé ochorenia.
Because the number of patients with pulmonary arterial hypertension is low, the disease is considered ‘rare’, and Thelin was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 21 October 2004.
Keďže je počet pacientov s pľúcnou arteriálnou hypertenziou nízky, toto ochorenie sa považuje za zriedkavé, a preto bol liek Thelin 21. októbra 2004 označený za liek na zriedkavé choroby.
Because the number of patients with short bowel disease is low, the disease is considered ‘rare’, and Revestive was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 11 December 2001.
Keďže je počet pacientov so syndrómom krátkeho čreva nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Revestive dňa 11. decembra 2001 označený za liek na ojedinelé ochorenia.
Because the number of patients with sickle cell syndrome is low, the disease is considered ‘rare’, and Siklos was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 9 July 2003.
Keďže počet pacientov so syndrómom kosáčikovitých buniek je nízky, toto ochorenie sa považuje za zriedkavé, a preto bol liek Siklos 9. júla 2003 označený za liek na ojedinelé ochorenia.
Because the number of patients with SMEI is low, the disease is considered ‘rare’, and Diacomit was designated as an ‘orphan medicine’ (a medicine used in rare diseases) on 5 December 2001.
Keďže je počet pacientov so SMEI nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Diacomit dňa 5. decembra 2001 označený za liek na ojedinelé ochorenia.
Because the number of patients with soft tissue sarcoma is low, the disease is considered ‘rare’, and Lartruvo was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 12 February 2015.
Keďže je počet pacientov so sarkómom mäkkých tkanív nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Lartruvo 12. februára 2015 označený za liek na ojedinelé ochorenia.
Because the number of patients with these cancers is low, they are considered ‘rare’, and Imbruvica was designated an ‘orphan medicine’ (a medicine used in rare diseases).
Keďže je počet pacientov s týmito typmi rakoviny nízky, ochorenia sa považujú za zriedkavé, a preto bol liek Imbruvica označený za liek na ojedinelé ochorenia.
Because the number of patients with these diseases is low, the diseases are considered ‘rare’, and Atriance was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 16 June 2005.
Keďže je počet pacientov s týmito chorobami nízky, tieto choroby sa považujú za zriedkavé a liek Atriance bol 16. júna 2005 označený za liek na ojedinelé ochorenia (liek, ktorý sa používa pri zriedkavých ochoreniach).
Because the number of patients with these diseases is low, the diseases are considered ‘rare’, and Revlimid was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 12 December 2003, 8 March 2004 and 27 October 2011.
Keďže je počet pacientov s týmito chorobami nízky, tieto choroby sa považujú za zriedkavé, a preto bol liek Revlimid dňa 12. decembra 2003, 8. marca 2004 a 27. októbra 2011 označený za liek na ojedinelé ochorenia.
Because the number of patients with these diseases is low, the diseases are considered ‘rare’, and Vidaza was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 6 February 2002 for myelodysplastic syndromes and on 29 November 2007 for AML.
Keďže je počet pacientov s týmito ochoreniami nízky, ochorenia sa považujú za zriedkavé, a preto bol liek Vidaza 6. februára 2002 označený za liek na ojedinelé ochorenia na liečbu myelodysplastických syndrómov a 29. novembra 2007 na liečbu AML.
Because the number of patients with these diseases is low, they are considered ‘rare’ and Carbaglu was designated an ‘orphan medicine’ (a medicine used in rare diseases) on various dates (see below).
Keďže je počet pacientov s týmito ochoreniami nízky, ochorenia sa považujú za zriedkavé, a preto bol liek Carbaglu k rôznym dátumom označený za liek na ojedinelé ochorenia (pozri ďalej).
Because the number of patients with these diseases is low, they are considered ‘rare’, and Cresemba was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 4 June 2014 (for mucormycosis) and 4 July 2014 (for aspergillosis).
Keďže je počet pacientov s týmito ochoreniami nízky, tieto ochorenia sa považujú za zriedkavé, a preto bol liek Cresemba dňa 4. júna 2014 (na mukormykózu) a 4. júla 2014 (na aspergilózu) označený za liek na ojedinelé ochorenia.
Because the number of patients with these diseases is low, they are considered ‘rare’, and Zavesca was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 18 October 2000 for type 1 Gaucher disease and on 16 February 2006 for Niemann-Pick type C disease.
Keďže počet pacientov s týmito ochoreniami je nízky, považujú sa za tzv. ojedinelé ochorenia a liek Zavesca bol 18. októbra 2000 označený za liek na ojedinelé ochorenia pre Gaucherovu chorobu typu 1 a 16. februára 2006 za liek na ojedinelé ochorenia pre Niemann-Pickovu chorobu typu C.
Because the number of patients with this condition is low, Luveris was not compared with any other medicines.
Keďže je počet pacientok s týmto ochorením nízky, liek Luveris sa neporovnával so žiadnym iným liekom.
Because the number of patients with transthyretin amyloidosis is low, the disease is considered ‘rare’, and Vyndaqel was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 28 August 2006.
Keďže je počet pacientov s transtyretínovou amyloidózou nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Vyndaqel 28. augusta 2006 označený za liek na ojedinelé ochorenia.
Because the number of patients with tuberculosis is low in the EU, the disease is considered ‘rare’, and Deltyba was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 1 February 2008.
Keďže v EÚ je počet pacientov s tuberkulózou nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Deltyba dňa 1. februára 2008 označený za liek na ojedinelé ochorenia.
Because the number of patients with tuberculosis is low in the EU, the disease is considered ‘rare’, and Granupas was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 17 December 2010.
Keďže je počet pacientov s tuberkulózou v EÚ nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Granupas 17. decembra 2010 označený za liek na ojedinelé ochorenia.
Because the number of patients with tuberculosis is low in the EU, the disease is considered ‘rare’, and Sirturo was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 26 August 2005.
Keďže je počet pacientov s tuberkulózou v EÚ nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Sirturo 26. augusta 2005 označený za liek na ojedinelé ochorenia.
Because the number of patients with tuberous sclerosis is low, the disease is considered ‘rare’, and Votubia was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 4 August 2010.
Keďže je počet pacientov s tuberóznou sklerózou nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Votubia 4. augusta 2010 označený za liek na ojedinelé ochorenia.
Because the number of patients with urea cycle disorders is low, the diseases are considered ‘rare’, and Ravicti was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 10 June 2010.
Keďže počet pacientov s poruchami močovinového cyklu je nízky, ochorenia sa považujú za zriedkavé, a preto bol liek Ravicti 10. júna 2010 označený za liek na zriedkavú chorobu.
Because the number of patients with VOD is low, the disease is considered ‘rare’, and Defitelio was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 29 July 2004.
Keďže je počet pacientov s venookluzívnou chorobou nízky, choroba sa považuje za zriedkavú, a preto bol liek Defitelio dňa 29. júla 2004 označený za liek na ojedinelé ochorenia.
Because the number of patients with Wilson’s disease is low, the disease is considered ‘rare’, and Wilzin was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 31 July 2001.
Keďže počet pacientov s Wilsonovou chorobou je nízky, ochorenie sa považuje za zriedkavé, a preto bol liek Wilzin 31. júla 2001 označený za liek na ojedinelé ochorenia.
Because the numbers of patients with CML and ALL are low, the diseases are considered ‘rare’, and Iclusig was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 2 February 2010.
Keďže je počet pacientov s ochoreniami CML a ALL nízky, ochorenia sa považujú za zriedkavé, a preto bol liek Iclusig 2. februára 2010 označený za liek na ojedinelé ochorenia.
Because the numbers of patients with renal cell carcinoma and mantle cell lymphoma are low, the diseases are considered ‘rare’, and Torisel was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 6 April 2006 (for renal cell carcinoma) and on 6 November 2006 (for mantle cell lymphoma).
Keďže počet pacientov s karcinómom renálnych buniek a lymfómom plášťových buniek je nízky, choroba sa považuje za zriedkavú, a preto bol liek Torisel označený za liek na zriedkavé choroby 6. apríla 2006 (pre karcinóm renálnych buniek) a 6. novembra 2006 (pre lymfóm plášťových buniek).
Because the numbers of patients with soft-tissue sarcoma and ovarian cancer are low, the diseases are considered ‘rare’, and Yondelis was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 30 May 2001 (for soft-tissue sarcoma) and on 17 October 2003 (for ovarian cancer).
Keďže počet pacientov so sarkómom mäkkých tkanív a rakovinou vaječníkov je nízky, tieto ochorenia sa považujú za zriedkavé a liek Yondelis bol 30. mája 2001 (v prípade sarkómu mäkkých tkanív) a 17. októbra 2003 (v prípade rakoviny vaječníkov) označený za liek na ojedinelé ochorenia.
Because the numbers of patients with these diseases are low, the diseases are considered ‘rare’, and Nexavar was designated an ‘orphan medicine’ (a medicine used in rare diseases).
Keďže je počet pacientov s týmito ochoreniami nízky, tieto ochorenia sa považujú za zriedkavé, a preto bol liek Nexavar bol označený za liek na ojedinelé ochorenia (liek, ktorý sa používa pri zriedkavých ochoreniach).
Because the numbers of patients with these diseases are low, the diseases are considered ‘rare’, and Signifor was designated an ‘orphan medicine’ (a medicine used in rare diseases).
Keďže je počet pacientov s týmito ochoreniami nízky, ochorenia sa považujú za zriedkavé, a preto bol liek Signifor označený za liek na ojedinelé ochorenia.
Because the numbers of patients with these medical conditions are low, the diseases are considered ‘rare’, and Soliris was designated an ‘orphan medicine’ (a medicine used in rare diseases) for PNH on 17 October 2003 and for aHUS on 24 July 2009.
Keďže je počet pacientov s týmito ochoreniami nízky, tieto ochorenia sa považujú za zriedkavé, a preto bol liek Soliris označený za liek na ojedinelé ochorenia, a to 17. októbra 2003 pre paroxyzmálnu nočnú hemoglobinúriu a 24. júla 2009 pre atypický hemolyticko-uremický syndróm.
Because the observed treatment effects were smaller than what is seen with alternative treatments (progestogen-containing treatments) the CHMP therefore concluded that Duavive should be reserved for women who cannot take these alternative medicines.
Keďže pozorované účinky liečby boli menšie ako v prípade iných terapií (terapií zahŕňajúcich progestogén), výbor CHMP dospel k záveru, že liek Duavive sa má používať len u žien, ktoré nemôžu užívať tieto alternatívne lieky.
Because the patch is administered transdermally, no effect of food and gastrointestinal conditions is expected.
Keďže náplasť sa aplikuje transdermálne, neočakáva sa žiadny vplyv jedál alebo ochorení gastrointestinálneho traktu.
Because the reconstituted solution is a dark red solution, some insoluble particles may not be seen.
Keďže rekonštituovaný roztok je tmavočervený roztok, môže sa stať, že niektoré nerozpustné častice nie je vidieť.
Because the risk of myopathy with statins is dose-related, the use of Pelzont with simvastatin 80 mg or ezetimibe/simvastatin 10/80 mg is not recommended in Chinese patients.
Pretože riziko myopatie so statínmi súvisí s dávkou, u čínskych pacientov sa neodporúča použitie lieku Pelzont so simvastatínom 80 mg alebo ezetimibom/simvastatínom 10 mg/80 mg.
Because the risk of myopathy with statins is dose-related, the use of Tredaptive with simvastatin 80 mg or ezetimibe/simvastatin 10/80 mg is not recommended in Chinese patients.
Pretože riziko myopatie so statínmi súvisí s dávkou, u čínskych pacientov sa neodporúča použitie lieku Tredaptive so simvastatínom 80 mg alebo ezetimibom/simvastatínom 10 mg/80 mg.
Because the risk of myopathy with statins is dose-related, the use of Trevaclyn with simvastatin 80 mg or ezetimibe/simvastatin 10/80 mg is not recommended in Chinese patients.
Pretože riziko myopatie so statínmi súvisí s dávkou, u čínskych pacientov sa neodporúča použitie lieku Trevaclyn so simvastatínom 80 mg alebo ezetimibom/simvastatínom 10 mg/80 mg.
Because the solution contains no preservative, Hizentra should be used/infused as soon as possible after opening the vial.
Keďže roztok neobsahuje žiadnu konzervačnú látku, Hizentra sa musí použiť/podať v infúzii čo najskôr po otvorení injekčnej liekovky.
Because the solution contains no preservative, Privigen should be infused as soon as possible.
Roztok neobsahuje žiadnu konzervačnú látku, preto je potrebné podať infúziu Privigenu ihneď, ako to bude možné.
Because the solution contains no preservative, Privigen should be infused immediately.
Roztok neobsahuje žiadnu konzervačnú látku, preto je potrebné podať infúziu Privigenu okamžite.
Because the solution contains no preservative, you must use/infuse it as soon as possible after opening the vial.
Keďže roztok neobsahuje žiadnu konzervačnú látku, musíte ho použiť/podať čo najskôr po otvorení injekčnej liekovky.
Because the solution contains no preservative, your healthcare professional must infuse it immediately after opening the vial.
Keďže roztok neobsahuje žiadne konzervačné látky, váš zdravotnícky pracovník vám ho musí podať vo forme infúzie čo najskôr po otvorení liekovky.
Because the solution is slightly viscous, it may take 5-10 seconds to administer the solution by subcutaneous injection.
Pretože roztok je slabo viskózny, môže podanie roztoku subkutánnou injekciou trvať 5-10 sekúnd.